Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bjh.17272 http://scihub22266oqcxt.onion/10.1111/bjh.17272 33482025!8014171!33482025     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Br+J+Haematol 2021 ; 192 (4): 706-713 Nephropedia Template TP {{tp|p=33482025|t=2021. Early mortality benefit with COVID-19 convalescent plasma: a matched control study |pdf=|usr=}}{{33482025}} gab.com Text Early mortality benefit with COVID-19 convalescent plasma: a matched control study JO: Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=33482025 #FOAvip Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is uncertain for the treatment of novel coronavirus disease 2019 (COVID-19). Our goal is to assess the efficacy of COVID-19 convalescent plasma (CCP). In all, 526 hospitalized patients with laboratory-confirmed SARS-CoV-2 at an academic health system were analyzed. Among them, 263 patients received CCP and were compared to 263 matched controls with standard treatment. The primary outcome was 28-day mortality with a subanalysis at 7 and 14 days. No statistical difference in 28-day mortality was seen in CCP cases (25.5%) compared to controls (27%, P = 0.06). Seven-day mortality was statistically better for CCP cases (9.1%) than controls (19.8%, P < 0.001) and continued at 14 days (14.8% vs. 23.6%, P = 0.01). After 72 h, CCP transfusion resulted in transitioning from nasal cannula to room air (median 4 days vs. 1 day, P = 0.02). The length of stay was longer in CCP cases than controls (14.3 days vs. 11.4 days, P < 0.001). Patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion. To date, this is the largest study demonstrating a mortality benefit for the use of CCP in patients with COVID-19 compared to matched controls. Twit Text FOAVip Early mortality benefit with COVID-19 convalescent plasma: a matched control study ????Br J Haematol http://www.kidney.de/pget.php?&tw=1&pmid=33482025 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33482025 #FOAvip English Wikipedia <ref>{{Cite pmid|33482025}}</ref> Early mortality benefit with COVID-19 convalescent plasma: a matched control study #MMPMID33482025 Shenoy AG; Hettinger AZ; Fernandez SJ; Blumenthal J; Baez V Br J Haematol 2021[Feb]; 192 (4): 706-713 PMID33482025show ga Convalescent plasma can provide passive immunity during viral outbreaks, but the benefit is uncertain for the treatment of novel coronavirus disease 2019 (COVID-19). Our goal is to assess the efficacy of COVID-19 convalescent plasma (CCP). In all, 526 hospitalized patients with laboratory-confirmed SARS-CoV-2 at an academic health system were analyzed. Among them, 263 patients received CCP and were compared to 263 matched controls with standard treatment. The primary outcome was 28-day mortality with a subanalysis at 7 and 14 days. No statistical difference in 28-day mortality was seen in CCP cases (25.5%) compared to controls (27%, P = 0.06). Seven-day mortality was statistically better for CCP cases (9.1%) than controls (19.8%, P < 0.001) and continued at 14 days (14.8% vs. 23.6%, P = 0.01). After 72 h, CCP transfusion resulted in transitioning from nasal cannula to room air (median 4 days vs. 1 day, P = 0.02). The length of stay was longer in CCP cases than controls (14.3 days vs. 11.4 days, P < 0.001). Patients with COVID-19 who received CCP had a decreased risk of death at 7 and 14 days, but not 28 days after transfusion. To date, this is the largest study demonstrating a mortality benefit for the use of CCP in patients with COVID-19 compared to matched controls. |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/blood/mortality/*therapy[MESH] |Disease-Free Survival[MESH] |Female[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |Risk Factors[MESH] |SARS-CoV-2/*metabolism[MESH] |Survival Rate[MESH]Early mortality benefit with COVID-19 convalescent plasma: a matched c(epmc).pdf DeepDyve Pubget Overpricing